Frank Witney serves as an Operating Partner at Ampersand Capital Partners, a New York-based private equity firm. See sector focus and contact routes.
Frank Witney serves as an Operating Partner at Ampersand Capital Partners, a New York-based private equity firm, having joined in 2016 after leading major life sciences companies as CEO of Affymetrix and Dionex. Ampersand specializes in growth investments within the life sciences and healthcare sectors, primarily targeting companies in the United States and Europe. While specific check sizes and lead/follow behavior for Witney individually are not publicly disclosed, he has acted as the lead partner on five deals according to PitchBook data. His notable portfolio involvement includes chairing the boards of Leinco Technologies and BioEcho Life Science GmbH, as well as serving on the boards of Alamar Biosciences, Cerus Corporation, Revvity, and Standard BioTools. Witney’s distinctive point of view centers on deep operational expertise in genomics and analytical instrumentation, evidenced by his successful sale of Affymetrix for $1.3 billion and Dionex for $2.1 billion. He holds a Ph.D. in molecular and cellular biology from Indiana University, which underpins his sector focus on biotechnology and life sciences tools. No public writing or distinctive inve
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in New York.
Investors like Frank Witney · Full investor directory · Investor access · Company funding database